Vaxcyte Corporate Presentation
Cell-Free Protein Synthesis Platform Unlocks Multiple Vaccine Applications
Design and Produce Proteins Beyond Reach of Conventional Methods
о
XpressCF Platform (1)
Cell-Free Protein Synthesis (CFPS):
•
•
Transcriptional & translational (ribosomal) machinery
from E coli stored as a frozen “extract"
Produces singular protein of interest at high yields
Uniquely enables site-specific conjugation via insertion
of multiple nnAA conjugation anchors
Uniquely permits protein production in non-
physiological conditions
Speed, Flexibility, Scalability:
Cell free extract
Temp
+
Redox Potential
MM
Adjustable Reaction
Conditions
pH
•
Rapidly screen vaccine candidates
Flexible reaction conditions
Scaled to 1000L using standard equipment
7
(1) Exclusively licensed from Sutro Biopharma for the field of vaccines addressing infectious diseases.
Conjugation Anchors
Platform Capabilities
Superior Conjugate Vaccines:
•
•
Site-specifically attach antigens onto protein carriers designed to:
- Enable consistent exposure of T-cell epitopes and/or B-cell
epitopes on protein carrier
- Avoid off target effects
Designed to enable use of less protein carrier without sacrificing
immunogenicity
• Enables broader-spectrum vaccines
Novel Protein Vaccines:
• Able to produce "tough-to-make" protein antigens that conform to
target pathogens
•
Increased likelihood of protective immune responseView entire presentation